This National Institutes of Health grant addresses the critical comorbidity of HIV infection and substance use disorders (SUD), which worsens health outcomes and causes neuropathological complications due to persistent HIV activity. The grant supports research focused on suppressing HIV transcription to combat viral latency. Specifically, it seeks to identify targets and pathways to inhibit HIV transcriptional activity within reservoirs, including the central nervous system, in individuals with SUD. Furthermore, the initiative encourages using advanced small molecule drug discovery to find novel pharmacological probes and therapeutic drugs. These compounds will effectively suppress HIV transcription in people affected by both HIV and SUD, improving their health outcomes.
Opportunity ID: 351602
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-25-007 |
| Funding Opportunity Title: | Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 21, 2023 |
| Last Updated Date: | Dec 21, 2023 |
| Original Closing Date for Applications: | Aug 13, 2024 |
| Current Closing Date for Applications: | Aug 13, 2024 |
| Archive Date: | Sep 18, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $400,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) State governments City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) For profit organizations other than small businesses Small businesses Public housing authorities/Indian housing authorities Special district governments Private institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance. The goal of this initiative is to support research aimed at (1) identification of targets and pathways by which transcriptional activity of HIV can be suppressed in HIV reservoirs including the CNS in people with SUD, and (2) application of emerging small molecule drug discovery approaches to identify novel compounds that can be utilized as pharmacological probes and as drugs to suppress HIV transcription in people with HIV-SUD comorbidity. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-007.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00284261 | Jul 13, 2024 | Aug 13, 2024 | View |
Package 1
Mandatory forms
351602 RR_SF424_5_0-5.0.pdf
351602 PHS398_CoverPageSupplement_5_0-5.0.pdf
351602 RR_OtherProjectInfo_1_4-1.4.pdf
351602 PerformanceSite_4_0-4.0.pdf
351602 RR_KeyPersonExpanded_4_0-4.0.pdf
351602 PHS398_ResearchPlan_5_0-5.0.pdf
351602 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
351602 RR_Budget_3_0-3.0.pdf
351602 RR_SubawardBudget30_3_0-3.0.pdf
351602 PHS398_ModularBudget_1_2-1.2.pdf
351602 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
